Notice of Participation of the National Institute of Allergy and Infectious Diseases (NIAID) in PAR-21-248 Pediatric Immune System – Ontogeny and Development (INTEND) (R01 Clinical Trial Not Allowed)
Notice Number:
NOT-AI-21-073

Key Dates

Release Date:

August 3, 2021

Related Announcements

PAR-21-248 - Pediatric Immune System – Ontogeny and Development (INTEND) (R01 Clinical Trial Not Allowed)

Issued by

National Institute of Allergy and Infectious Diseases (NIAID)

Purpose

This Notice is to inform potential applicants that the National Institute of Allergy and Infectious Diseases (NIAID) is participating, effective immediately, in PAR-21-248, Pediatric Immune System – Ontogeny and Development (INTEND) (R01 Clinical Trial Not Allowed).

The following text has been added to reflect NIAID's participation in this FOA:

Part 1. Overview Information

Components of Participating Organizations
National Institute of Allergy and Infectious Diseases (NIAID)

Assistance Listing Number(s)
93. 855

Part 2. Full Text of Announcement

Section I. Funding Opportunity Description

Research Interests Scope

National Institute of Allergy and Infectious Diseases

In addition to the NICHD Research Scope, NIAID interests include:

• HIV research studies that include animal models may only use non-human primates
• Mechanisms regulating the generation and maintenance of B and T cell memory
• Molecular mechanisms of innate immunity, including trained immunity
• Mechanisms of tissue/organ-specific and mucosal immunity
• Epigenetic and/or metabolic regulation of the immune response
• Role and mechanisms of action of immune potentiators for understanding and improving early immune functionality
• Impact of maternal factors on immune system development and functioning in early life that include examination of longer-term effects in children
• Immunological correlates that modify/influence the host response to viral respiratory infections
• Impact of viral infection on the development of the immature immune system
• Impact of early life respiratory infection on subsequent infections.


Section VII. Agency Contacts


Scientific/Research Contact(s)

Mercy PrabhuDas, Ph.D., M.B.A.
Division of Allergy, Immunology and Transplantation (DAIT)
National Institute of Allergy and Infectious Diseases (NIAID)
Telephone: 240-627-3534
Email: [email protected]

Sonnie Kim, M.S.
Division of Microbiology and Infectious Diseases (DMID)
National Institute of Allergy and Infectious Diseases (NIAID)
Telephone: 240-627-3287
Email: [email protected]

Anjali Singh, Ph.D.
Division of AIDS
National Institute of Allergy and Infectious Diseases (NIAID)
Telephone: 240-627-3030
Email: [email protected]

Que Dang, Ph.D.
Division of AIDS
National Institute of Allergy and Infectious Diseases (NIAID)
Telephone: 240-292-6181
Email: [email protected]

Financial/Grants Management Contact(s)
Tamia Powell
National Institute of Allergy and Infectious Diseases (NIAID)
Telephone: 240-669-2982
Email: [email protected]

All other aspects of the FOA remain the same.

Inquiries

Please direct all inquiries to:

Mercy PrabhuDas, Ph.D., M.B.A.
National Institute of Allergy and Infectious Diseases (NIAID)
Telephone: 240-627-3534
Email: [email protected]


Weekly TOC for this Announcement
NIH Funding Opportunities and Notices